dm+d

35058611000001103

Refrigerated Storage

OcrevusRoche Products Ltd

Roche Products Ltd
Ocrevus
Concentrate for solution for infusion, 300mg

Contact Roche Products Ltd in all cases where a deviation from the recommended storage conditions has occurred. Refer to the electronic medicines compendium (eMC) at https://www.medicines.org.uk for company contact details.

12 October 2022
London MI Service

New Medicines

OcrevusRelapsing multiple sclerosis (MS) - higher dose regimen (1200mg or 1800mg six monthly)

Information

Ocrevus
New dosing regimen
Roche
Roche

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Recombinant humanised monoclonal antibody that selectively targets CD20-expressing B cells
MS estimated prevalence is 190 cases per 100,000 population. MS is more than twice as common in females than males. The highest prevalence for MS occurs in the 60 to 69 years age group for both sexes. The MS estimated incidence in England is between 8 and 11 new cases per 100,000 population [1].
Relapsing multiple sclerosis (MS) - higher dose regimen (1200mg or 1800mg six monthly)
Intravenous infusion